Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that future heart disease research should account for sex-specific differences to improve diagnosis, treatment, and outcomes.

The research suggests that the global distribution of PCOS is likely due to historical human migration and that genes affecting PCOS may have different impacts on males and females.

Androgens significantly affect female hair loss, and hormonal treatments may help.

Ketoconazole reduced hair growth and improved acne in women, but caused side effects needing careful monitoring.

Melatonin improved mental health and metabolism in women with PCOS.

Hormonal therapies are safe and effective for treating adult women's acne.

Cyproterone acetate is effective for treating hirsutism and acne but less so for hair loss, with side effects similar to birth control pills.

The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.

Women with PCOS often have mood disorders and a lower quality of life, and treatment should focus on both physical and mental health.

Non-classic congenital adrenal hyperplasia is a common disorder causing symptoms like acne and infertility, and it's managed based on symptoms, not just test results. Treatment can improve fertility and reduce miscarriage risk.

The research found that polycystic ovary syndrome (PCOS) has two distinct types, with one having more severe hormone and insulin issues.

The document concludes that correct diagnosis and management of PCOS are important, and more research is needed on its risks and treatments.

Excessive hair growth can be assessed by history, exam, and blood tests, and treated with medication like dexamethasone, birth control pills, and spironolactone.

Oral contraceptives can cause skin issues like dark patches, acne, yeast infections, sensitivity to light, spider veins, skin rashes, and hair loss.

Some plants used in traditional medicine may help treat cancer because they contain proteins that can inactivate ribosomes.

Metformin and rosiglitazone both improved insulin use and hormonal symptoms in women with PCOS.

Certain genetic variations in the SHBG gene are linked to an increased or decreased risk of PCOS in Mediterranean women.

About 8.5% of women in Salvador, Brazil, have Polycystic Ovary Syndrome.

Hirsutism can be caused by various conditions besides PCOS, and it's important to treat the underlying issue and manage symptoms with medication and cosmetic approaches.

Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.

Insulin-lowering medications show promise for PCOS symptoms but can't be the main treatment yet due to limited long-term research.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Women with only irregular periods or excess hair have a better hormone profile than those with full PCOS, but both groups are similar, indicating a need for better PCOS diagnosis methods.

The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.

The document concludes that treating PCOS requires a combination of drugs to manage reproductive and metabolic symptoms, with more research needed on combination therapies.

Natural molecules like inositols, resveratrol, vitamins, and omega-3 fatty acids may help manage Polycystic Ovary Syndrome (PCOS), but their effects vary and need more exploration.

The study found that women with PCOS have more and larger ovarian follicles and differences in ovarian structure, but these features alone can't always diagnose PCOS.

The conclusion is that accurately identifying the cause of high androgen levels in women with PCOS is crucial and requires specific tests.

Metformin should be used for PCOS mainly in those with glucose intolerance, and has limited benefits for infertility or hirsutism.

The conclusion is that formalizing how past decisions influence current health technology assessments could improve the credibility and defense of coverage decisions.